Zentalis Pharmaceuticals (ZNTL) Common Equity (2019 - 2026)

Zentalis Pharmaceuticals has reported Common Equity for 8 years, with the latest figure at $182.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 38.15% year-over-year to $182.7 million; the trailing twelve-month figure through Mar 2026 stood at $182.7 million (down 38.15% YoY), and the FY2025 full-year result was $216.2 million, down 35.88% from the prior year.
• Common Equity for Q1 2026 stood at $182.7 million, down from $216.2 million in the prior quarter.
• The five-year high for Common Equity was $523.3 million in Q2 2023, with the low at $182.7 million in Q1 2026.
• Average Common Equity over 5 years is $366.7 million, with a median of $382.6 million recorded in 2024.
• Year-over-year, Common Equity surged 90.96% in 2022 and plunged 38.15% in 2026.
• Tracing ZNTL's Common Equity over 5 years: stood at $434.0 million in 2022, then advanced by 0.75% to $437.3 million in 2023, then slipped by 22.89% to $337.2 million in 2024, then slumped by 35.88% to $216.2 million in 2025, then dropped by 15.51% to $182.7 million in 2026.
• The last three Common Equity figures came in at $182.7 million (Q1 2026), $216.2 million (Q4 2025), and $252.9 million (Q3 2025), per Business Quant data.

Peer Comparison